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Abstract
MT-45 is a synthetic opioid with a pharmacological activity comparable to morphine and it has
been involved in intoxications and fatalities reported in Europe and in USA. It was recently subject
to control measures, but to date the metabolic pathways of the substance are still unknown. Using
rat hepatocytes and LC–HRMS, 14 novel Phase I and II MT-45 metabolites were identified, pro-
ducts of monohydroxylation, dihydroxylation and N-dealkylation; glucuronide conjugation of
mono- and dihydroxylated metabolites also occurred. The detected metabolites were firstly pre-
dicted in silico, then incubation of the drug with rat hepatocytes was carried out and the obtained
metabolites were identified by LC–HRMS, with retention times, mass shift between theoretical
mass and observed mass (<5 ppm), peak abundance and fragmentation pattern. Hydroxylated
MT-45 was found to be the major metabolite of MT-45 in vitro experiments. The presence of all
metabolites was confirmed by in vivo experiments in urine samples of CD-1 male mice; in these
samples hydroxy-MT-45-glucuronide and di-hydroxy-MT-45-glucuronide are the most abundant
metabolites, while the parent drug is found at concentration <10 ngmL−1 after 300min. The knowl-
edge of Phase I and II MT-45 metabolite structure is then crucial to develop analytical methods to
identify MT-45 consumption in clinical and forensic testing.
Introduction
The so-called new psychoactive substances (NPS) do not represent a
novelty in the drug market anymore, in fact the phenomenon has been
largely reported and monitored worldwide since the late 1990s (1).
Several progresses were made to manage the issues arising from the dif-
fusion of the new drugs, efficient and innovative legal responses have
been provided by different nations with the European Union in first
line. In Europe, the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) has a central role in monitoring NPS and in pro-
viding information and risk-assessment reports on new drugs in accor-
dance with Article 6 of Council Decision 2005/387/JHA (2). However,
the speed at which NPS suppliers offer new alternatives is still a major
concern for both legislators and analysts. From an analytical point of
view, the most effective tool to face the NPS emergency is the use of sen-
sitive and selective techniques such as high resolution mass spectrometry
(HRMS) (3). By enabling accurate mass determination at high resolving
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power, HRMS may be used to identify the exact mass of a molecule and
its fragments, allowing the confirmation, or even the identification of a
new substance, overcoming the limitations of multi-target screening (4).
In practice, however, untargeted screening is not an easy task, espe-
cially when complex samples, such as biological matrices, are involved;
newly introduced NPS still represent a challenge since analytical stan-
dards are not available, they are not included in commercial or in-
house libraries and metabolic pathways are unknown.
MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine), a drug which
was firstly developed in the early 1970s by the Japanese company
Dainippon Pharmaceutical Co. Ltd, is a new abused synthetic opioid,
with an analgesic activity comparable to morphine but with a higher tox-
icity in animals (5). MT-45 has been raising health concerns worldwide
after serious harmful effects, comprising intoxications and fatalities, were
reported in Europe (28 deaths have been associated with MT-45 in
Sweden alone) (5) and in the United States (6, 7) over a short period of
time; it was the 10th new psychoactive substance to be risk assessed by
EMCDDA. As a result of the risk-assessment conclusions, which reported
the toxicity as well as the dependence potential of the substance, MT-45
was recently subject to control measures across the Member States
(Council implementing decision (EU) 2015/1873); however, up to date
the metabolic pathways of the substance are still unknown (7).
The aim of this work was to ascertain the chemical structures of
the metabolites of MT-45, in order to allow further pharmacological
studies and to better assess the health implications of the abuse of
this substance. In addition, the identification of the most abundant
metabolites is of the utmost importance for developing analytical
methods for clinical and forensic investigations (8). In fact, when
metabolism is unknown, the determination of target analytes is criti-
cal; the few reports of MT-45 in biological fluids are mainly related
to blood specimens where the unchanged compound may be
detected in considerable amounts (6). MT-45 was detected in
unchanged form also in urine samples from intoxicated patients (9).
The present study involved a classic approach comprising both
in silico and in vitro experiments. Similar approaches were used to
identify the metabolites of several NPS such as α-PVP, 2-DPMP,
3,4-DMMC and MPA (10), 4-methoxy-α-PVP (11), PV8 (12), AH-
7921 (13), JWH-015, JWH-098, JWH-251, JWH-307 (14), ADB-
FUBINACA, AB-FUBINACA, AB-PINACA, QUPIC, 5 F-QUPIC
(15) and AKB-48 (16). In this study, the most abundant metabolites
were firstly predicted in silico, incubation of the drug with rat hepa-
tocytes was then carried out and the obtained metabolites were iden-
tified by LC–HRMS. As further confirmation, in vivo experiments
were performed; several urine samples of CD-1 male mice in which
MT-45 (6mg/kg, i.p.) were administered, were analyzed. The useful-
ness of in vivo experiments, to confirm in vitro studies, was previ-
ously showed (13, 17). To compare the in vivo effect of MT-45 with
the presence of its urine metabolites, behavioral tests (mechanical
analgesia and breath rate analysis) were performed in CD-1 male
mice. Moreover, in order to better understand the in vivo efficacy of
MT-45, morphine was used as reference compound.
To the best of our knowledge, this is the first study to report the
metabolic profile of MT-45. Urine drug clearance data for MT-45 in
mouse are also provided.
Materials and Methods
Chemicals and reagents
MT-45, cocaine and morphine were obtained by LGC standard
(Sesto San Giovanni, Milan, Italy). MT-45 for in vitro and in vivo
experiments was purchased from Composynth Chemicals
(Mississauga, ON, Canada) and it was analyzed, to confirm its iden-
tity and purity (>95%), using the presented HPLC–MS-MS by com-
parison with the standard. Pooled cryopreserved male rat (Sprague-
Dawley) hepatocytes, Williams’ E Medium (phenol red free), cell
maintenance supplement pack (Dexamethasone, Cocktail B:
penicillin-streptomycin, ITS + (insulin, transferrin, selenium com-
plex, BSA and linoleic acid), GlutaMAX™ and HEPES), as well as
thawing and plating supplement pack (Prequalified fetal bovine
serum (FBS), Dexamethasone, Cocktail A: FBS, penicillin-
streptomycin, human recombinant insulin, GlutaMAX™ and
HEPES) were purchased from Life Technologies (Monza, Italy).
Formic acid, methanol, acetonitrile and water were purchased
from Fisher Scientific (Fair Lawn, NJ, USA). All solvents employed
in the incubation were ultra-performance liquid chromatography
(UHPLC) grade, and LC–MS grade in the chromatographic system.
For in vivo studies, drugs were dissolved in saline solution (0.9%
NaCl) and administrated intraperitoneally at a volume of 4 μL g−1;
saline solution was also used as the vehicle. Dose of morphine and
MT-45 (6mg kg−1 i.p.) was chosen based on preliminary studies
(unpublished data).
In silico prediction study
Metaprint2D Freeware (S. Adams, Centre for Molecular Science
Information, University of Cambridge) was used for in silico predic-
tion of MT-45 metabolites. The structure of MT-45 was imported
as SMILE code and predictions were generated using rat liver model.
The most probable sites and relative reactions were estimated based
on the NOR, a probability score assigned by Metaprint2D; a high
NOR indicated, a more frequently reported site of metabolism in
the metabolite database.
The chosen sites had a NOR score between 1 and 0.15. The pre-
dicted metabolites were reimported as SMILE code to predict Phase
II metabolites with highest NOR score. SMILE code was generated
using Marvin Sketch (v. 16.6.13.0, ChemAxon Ltd).
Rat hepatocyte incubation
For in vitro incubation experiments, MT-45 (20 μmol L−1) was
incubated at 37°C with rat cryopreserved hepatocytes. Cells were
thawed in and washed with Williams’ E Medium, containing
dexamethasone (1 μM), penicillin/streptomycin (1%), human recom-
binant insulin (4 μg mL−1), Glutamax™ (2 mM), Hepes pH 7.4
(15 mM) and FBS (5%) and centrifuged at 55×g for 3 min at
room temperature. After centrifugation and removal of the super-
natant, the cell pellet was resuspended in Williams’ E Medium,
containing dexamethasone (0.1 μM), penicillin/streptomycin (0.5%),
human recombinant insulin (6.25 μg mL−1), human transferrin
(6.25 μg mL−1), selenous acid (6.25 ng mL−1), BSA 1.25mgmL−1,
linoleic acid (5.35 μg mL−1), Glutamax™ (2 mM) and Hepes pH
7.4 (15 mM) Cell viability was assessed with the Trypan blue 0.4%
exclusion method.
About 10 μL of MT-45 1mM was incubated in 500 μL of a
1.106 cell mL−1 suspension, at 37°C in a water bath under constant
gentle shaking. Cocaine was also incubated, as a positive control, to
verify metabolic capability under our experimental conditions.
Samples were collected at 0.5, 1, 2 and 3 h; reaction was quenched
by adding 500 μL acetonitrile. Specimens were stored at −20°C until
analysis.
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Before injection, samples were centrifuged; the supernatant was
removed, diluted 1:2 with water and filtered with Minisart SRP25
4mm (0.45 μm) syringe filters (Sartorius, Turin, Italy).
In vivo studies
Animals
The Male ICR (CD-1®) mice, 25–30 g (Harlan Italy; S. Pietro al
Natisone, Italy) were group-housed (8–10 mice per cage; floor area
per animal was 80 cm2; minimum enclosure height was 12 cm) in a
colony room under constant temperature (20–22°C) and humidity
(45–55%). Food (Diet 4RF25 GLP, Milan, Italy) and tap water
were available ad libitum all the time the animals spent in their
home cages. The daylight cycle was maintained artificially (dark
between 6 p.m.–6 a.m.). Experiments were performed during the
light phase and each mouse was used for only one experiment.
Experimental protocols performed in the present study were in
accordance with the new European Communities Council Directive
of September 2010 (2010/63/EU) a revision of the Directive 86/609/
EEC, and were approved by the Italian Ministry of Health (license
n. 335/2016-PR) and by the Ethics Committee of the University of
Ferrara. Moreover, adequate measures were taken to minimize the
number of animals used and their pain and discomfort. About 6
mice were used in experiment for urine collection, while 16 mice (8
for MT-45 and 8 for morphine evaluation) were used for acute
mechanical nociception and breath rate evaluation.
Urine collection and sample preparation
Urine was collected by placing each mouse in a cage with a plastic
grid in the floor that allows the recovery of urine. As soon as the urine
of mice was deposited under the grid, it was immediately collected and
pipetted into sterilized vials that were stored at −20°C. The time at
which the urine was collected is recorded. The day of experiment at
least 200 μL of urine were collected for each mouse (internal control
sample) before MT-45 administration at 6mg kg−1 i.p.
Before injection, urine samples were diluted 1:4 with methanol
and filtered with Minisart SRP25 4mm (0.45 μm) syringe filters
(Sartorius, Turin, Italy).
Evaluation of pain induced by a mechanical stimulus
Acute mechanical nociception was evaluated using the tail pinch test
(18). Pinch pressure was applied to the third of the tail extending from
the root via a special rigid probe connected to a digital dynamometer
(ZP-50N, IMADA, Japan). Mice did not vocalize during the applica-
tion of tail pinch pressure and when the mouse flicked its tail, the pres-
sure was stopped and the digital instrument saved the maximum peak
of weight supported (g force−1). A cut off (500 g force−1) was set to
avoid tissue damage. The test was repeated 3 times and the final value
was calculated with the average of 3 obtained scores. Acute mechani-
cal nociception was measured at 0, 35, 55, 90, 145, 205, 265 and
325min post injection.
Evaluation of breath rate
The experimental protocol for the detection of respiratory parameter
in this study provides for monitoring of the animal awake, freely
moving, with a non-invasive and minimal handling.
The animal is leaving free in a cage and the respiration patterns
of the mice were videotaped by a camera (B/W USB Camera day&-
night with varifocal lens; Ugo Basile, Italy) placed above the obser-
vation’s cage. A trained operator who does not know the drug
treatments performed analyzes movies off-line. The analysis frame
by frame allows to better evaluate the number of breath rates of the
mouse evaluated through the count of abdomen movement. Basal
respiratory rates in mice was of about 257 ± 11 breath rates per
minutes (brp). Breath rates were measured at 0, 10, 35, 65, 85, 125,
185, 245 and 305min post injection.
Data and statistical analysis
Data are expressed in percentage of baseline (breath rates) and in per-
cent of maximal possible effect {EMax% = [(test − control latency)/
(cut off time − control)] × 100} in the tail pinch test. Statistical analy-
sis was performed by two-way ANOVA followed by the Bonferroni’s
test for multiple comparisons for the analysis of the dose response
curve of each compounds at different times (Panel A, B). We performed
the statistical analysis on the average responses obtained, at each time
point and dose compared. The statistical analysis was executed by
means of the Prism software (GraphPad, San Diego, CA, USA).
LC–HRMS metabolite profiling
HPLC-HRMS analysis was carried out on a Thermo Scientific
Ultimate 3000 RSLC system coupled to a Thermo Scientific Q-
Exactive Mass spectrometer (Thermo Fisher Scientific, Bremen,
Germany).
The column used for chromatographic separation was a C18-
PFP (100 × 3mm ID) from Ace (Aberdeen, Scotland) packed with
particles of 3 μm, held at 40°C at a flow rate of 0.6mLmin−1.
Mobile phases were: 0.1% formic acid in water (Phase A) and 0.1%
formic acid in acetonitrile (Phase B). The initial composition (5% B)
was increased from 5% to 50% B over 4.5min, from 50% to 100%
over 0.5min, held at 100% for 2min and returned to initial condi-
tions over 1min. A 2min equilibration followed, yielding a total
run time of 10min. The injection volume was 6 μL.
The Q-Exactive mass spectrometer was equipped with a heated
electrospray ionization source (HESI-II) operated in positive mode.
The operating parameters of the ion source were set as follows:
spray voltage 3.5 kV, capillary temperature 350°C, heater tempera-
ture 450°C, S-lens RF level 60, sheath gas flow rate 55, auxiliary
gas flow rate 20. Nitrogen was used for spray stabilization, for
collision-induced dissociation experiments in the high energy colli-
sion dissociation (HCD) cell and as the damping gas in the C-trap.
The instrument was calibrated in the positive and negative mode
every working day. On every sample a full-scan acquisition, in the
range of m/z 50–600, was carried out at a resolution of 35,000
(FWHM at m/z 450) in order to detect the metabolites predicted
in silico as well as potential unpredicted metabolites. Automatic Gain
Control (AGC) and maximum injection time were set at 1 × 105 and
50ms, respectively.
For identification purposes, metabolite precursor ions, which
were detected in full scan, were listed in an inclusion list in order to
perform target MS/MS experiments. Precursors were filtered in the
quadrupole with a 0.4m/z isolation window and then fragmented in
the HCD cell with different normalized collision energy (NCE) rang-
ing from 20% to 55%. A scan of all the fragment ions was per-
formed in the Orbitrap analyzer in the range of m/z 50–550. For
these tests the MS/MS experiment performed in a separate run.
LC–MS-MS semi-quantitative method
The HPLC equipment consisted of a Series 200 Micro-LC Pump
and a Series 200 autosampler from Perkin Elmer (Norwalk, CT,
3Identification of MT-45 Metabolites
Downloaded from https://academic.oup.com/jat/article-abstract/doi/10.1093/jat/bkx058/3978805/Identification-of-MT-45-Metabolites-In-Silico
by Sapienza Università di Roma user
on 12 September 2017
USA). An API 2000 from AB-Sciex (Toronto, ON, Canada)
equipped with a TurboIon-Spray source was used for analysis.
MT-45 and metabolites were separated using a reverse-phase F5
Kinetex column from Phenomenex packed with core shell particles
(2.6 μm, 2.1 × 100mm). A Phenomenex security GuardUltra
Cartridge was also used to protect the column. The mobile phases
were water (Phase A) and acetonitrile (Phase B) both containing
5mM formic acid; the flow rate was 300 μLmin−1 but only 100 μL
min−1 were transferred to the ion source by means of a splitting sys-
tem. The analyte separation was performed using a gradient elution
according to the following steps: for 0.5 min Phase B is maintained
at 0%, Phase B is then increased from 0 to 35% in 0.5min, then to
60% in 4.5min and to 100% in 1.5min. Phase B is kept at 100%
for 2min; afterwards, the system is switched back to the initial con-
ditions in 3 min. All the substances were detected in positive ioniza-
tion (PI) with a capillary voltage of 5500V, nebulizer gas (air) at
65 psi, turbo gas (nitrogen) at 35 psi and 425°C. The injection vol-
ume was 6 μL.
The optimum conditions for detection were determined with
MT-45 and later used with slight modifications with metabolites. A
MT-45 solution at 10 ng mL−1 in methanol was prepared for this
purpose. Data collection and elaboration were performed by means
of Analyst 1.5 software (PE Sciex). The chromatographic profiles
were recorded by use of different MS(/MS) acquisition modes. SIM
mode on Q1 was used to detect the metabolites previously identified
in HRMS (m/z 365, 381, 169, 185, 541, 557) and to optimize the
chromatographic conditions. Product-ion scan (PIS) experiments at
different collision energies were carried out to confirm the data and
to identify the optimal conditions for detection.
Finally, to obtain the maximum instrumental sensitivity, multiple
reaction monitoring (MRM) acquisition was applied using the MS/
MS information obtained from the previous runs. The selected
masses, together with the main LC–MS/MS conditions, are reported
in Table S1. This acquisition method was used to obtain pharmaco-
kinetic data and to analyze urine samples.
Results and Discussion
In silico results
MetaPrint2D identified 9 potential Phase I metabolites of MT-45;
the most probable metabolite, with NOR between 1 and 0.66, arose
from the hydroxylation on the para position of the cyclohexane
ring. According to the software, hydroxylation could occur also on
the aromatic rings, leading to two additional hydroxylated metabo-
lites, with a NOR between 0.33 and 0.15. A N-dealkylated metabo-
lite was also predicted, with a NOR between 0.33 and 0.15.
Considering the high NOR scores (between 1 and 0.33) obtained
for these metabolites, their structures were reintroduced in the soft-
ware, leading to the identification of additional possible metabolites.
A second hydroxylation on each cycle (cyclohexane or both aro-
matic rings) could lead to 3 dihydroxylated metabolites and hydrox-
ylation was retained possible also for the N-dealkylated metabolite
(on cyclohexane). A trihydroxylated metabolite (one hydroxylation
on each cycle) was also predicted by the software. For Phase II meta-
bolism prediction, Phase I metabolites were reintroduced in
MetaPrint2D; according to the software the sole acceptable Phase II
reaction was glucuronidation on hydroxylated sites.
Metabolites identification in vitro
Hepatocytes incubation allowed to mimic the physiological liver
environment and to generate a realistic metabolic fingerprint of MT-
45. The exploitation of in silico results enabled to detect and identify
the major metabolites without using any software or data mining
tools. Accurate masses were extracted from full-scan experiments
and product-ion spectra were generated in tandem MS experiments.
The structures of the observed metabolites were confirmed based on
the observed retention times, mass shift between theoretical mass
and observed mass (<5 ppm), peak abundance and fragmentation
pattern.
Cocaine (positive control) and its metabolites, benzoylecgonine
(BEG), norcocaine and ecgonine methyl ester (EME), were observed
in the hepatocyte samples confirming hepatocyte metabolic activity.
Fourteen major MT-45 metabolites (10 Phase I and 4 Phase II)
with mass measurements shifts <5 ppm were identified in the hepa-
tocyte samples (Table I). Retention time was between 0.44 and 3.87
for metabolites while MT-45 eluted at 4.64min. Consistent with
ongoing metabolism, MT-45 peak area decreased during incubation
while in general metabolite peak areas increased from 0.5 to 3 h
(Figure 1). All 14 metabolites, especially Phase I, were identified in
the 0.5 h sample, showing an extensive metabolism.
The metabolic reactions observed included: hydroxylation (M1,
M2, M3), dihydroxylation (M4, M5, M6, M7, M8), N-dealkylation
(M9), hydroxylation+N-dealkylation (M10); glucuronide conjugates
Table I. MT-45 metabolites identified after incubation with rat hepatocytes. Fragment ions are expressed in nominal mass
Rt (min) Elemental composition m/z Mass error (ppm) Characteristic fragments
P MT-45 4.64 C24H32N2 349.2634 −2.9 181, 166, 169, 103, 87
M1 hydroxy-MT-45 isomer 1 3.48 C24H32N2O 365.2577 −4.4 169, 197, 119, 91
M2 hydroxy-MT-45 isomer 2 3.76 C24H32N2O 365.2579 −3.7 197,181, 166, 119, 91
M3 hydroxy-MT-45 isomer 3 3.87 C24H32N2O 365.2577 −4.4 181, 169, 105, 197, 167, 347
M4 di-hydroxy-MT-45 isomer 1 2.65 C24H32N2O2 381.2537 −1.4 197, 119
M5 di-hydroxy-MT-45 isomer 2 2.80 C24H32N2O2 381.2533 −2.4 197, 119
M6 di-hydroxy-MT-45 isomer 3 2.93 C24H32N2O2 381.2527 −3.8 363, 169, 121
M7 di-hydroxy-MT-45 isomer 4 3.12 C24H32N2O2 381.2525 −4.5 105, 185, 363
M8 di-hydroxy-MT-45 isomer 5 3.23 C24H32N2O2 381.2529 −3.4 105, 185, 363
M9 1-cyclohexyl-piperazine 0.64 C10H20N2 169.1697 −4.8 87, 83
M10 hydroxy-(1-cyclohexyl-piperazine) 0.44 C10H20N2O 185.1639 −4.2 87
M11 hydroxy-MT-45-glucuronide isomer 1 2.65 C30H40N2O7 541.2899 −2.7 365, 197, 169
M12 hydroxy-MT-45-glucuronide isomer 2 2.83 C30H40N2O7 541.2898 −2.9 119, 197
M13 di-hydroxy-MT-45-glucuronide isomer 1 2.12 C30H40N2O8 557.2845 −3.25 169, 135, 213
M14 di-hydroxy-MT-45-glucuronide isomer 2 2.57 C30H40N2O8 557.2843 −3.5 213, 167, 195, 381
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were also observed (M10, M11, M12, M13). Compared to Phase I
metabolites, glucuronide conjugates showed significantly lower
areas. Based on observed peak areas, M1, M2, M3 were the most
intense metabolites in hepatocyte incubation samples, followed by
M9 and M4, M5, M6, M7, M8. These results were in accordance
with the in silico prediction. However the trihydroxylated metabo-
lite, predicted in silico, was not found in vitro. Hydroxylation on
the aromatic ring was reported to be one of the initial metabolic
step for structurally related 1,2-diphenylethylamines (19), support-
ing the obtained results.
In order to characterize the observed metabolites, target MS/MS
experiments were performed at different NCE. A number of charac-
teristic product ions were observed for MT-45 (Figure 2). The cleav-
age between the piperazine moiety and the diphenylethane led to the
ions at m/z 181.1005 and 169.1695. The fragmentation between a
phenyl and the ethane bridge generated the ion at m/z 103.0543. On
the other hand the ion at m/z 166.0773, could be explained as a
result of a rearrangement of the diphenylethane moiety for increased
stability, and arose from the formation of alternating double bonds
and loss of CH3 as a radical. A similar fragmentation pattern was
observed for structurally related 1,2-diphenylethylamines (19).
Finally, the ion at m/z 87.0920 corresponded to the piperazine,
resulting from the losses of both the cyclohexane and the dipheny-
lethane moieties.
OH-MT-45 (M1, M2, M3), was the most intense metabolite in
the hepatocyte samples. Three isomers, chromatographically sepa-
rated, were observed in all the samples. The fragmentation pattern
at different NCE are shown in Figure 3: the three isomers showed
all the characteristic fragments of the precursor MT-45 but also a
number of ions that suggested that a hydroxylation occurred on one
of the aromatic ring. In fact the metabolic introduction of a hydroxy
group into the diphenylethane moiety led to a shift of 16 u from the
ion at m/z 181.1008 to m/z 197.0956 and from m/z 103.0542 to m/
z 119.0491. These two ions were observed in the fragmentation pat-
tern of the three isomers and were particularly abundant in M2 and
M3. In M1 spectra at high NCE, the most abundant ion was at m/z
105.0336; accurate mass measurements confirmed that this ions cor-
responded to C7H50, showing that also for M1 the hydroxylation
occurred on one of the aromatic ring.
M4, M5, M6, M7 and M8 are different positional isomers of di-
OH-MT45. Five isomers of the ion at m/z 381 were observed;
considering the poor chromatographic separation it was not possible
to assign a structure to each peak, in particular M7 and M8 as well
as M4 and M5, were not well resolved chromatographically and
showed similar fragmentation patterns (Figure 4). Accurate mass
measurements allowed to identify a number of characteristic frag-
ments. The most intense ions in the spectra of M4 and M5 were
197.0957 and 119.0491, which suggested at least one hydroxylation
on the diphenylethane moiety. M6 showed the fragments at m/z
363.2421, 169.1693 and 121.0286; this last exact mass corresponded
to the formula C7H5O2, which indicated that two hydroxylations
occurred on the same aromatic ring. M7 and M8 characteristic frag-
ments included m/z 105.0336, 185.1645 and 363.2412, which sug-
gested that hydroxylations occurred on both the cyclohexane (185)
and a phenyl (105) as already discussed by Lim et al. (20).
M9 and M10 were identified as (1-cyclohexyl-4-ethylpiperazine)
and OH-(1-cyclohexyl-4-ethylpiperazine) and arose from the
N-dealkylation of MT-45. Being quite hydrophilic they eluted early
in the run (0.64 and 0.42min, respectively), but it should be stressed
that in the chromatographic conditions applied, the dead time of the
column was < 0.2min. Figure 5 illustrates the product-ion spectra
for these metabolites. Only a few fragments could be observed,
namely 87.0920 and 83.0859, which corresponded to the piperazine
and the cyclohexane moieties.
M11, M12, M13 and M14 were Phase II metabolites. From the
fragmentation pattern (Figure 6) it resulted that glucuronide conju-
gation always occurred on the aromatic ring. M11 and M12 are
both mono-hydroxylated conjugates and they showed the fragment
at m/z 197.0957 which resulted from the introduction of a hydroxy
group into the diphenylethane moiety. On the other hand the bis-
hydroxylated glucuronides, showed a number of characteristic frag-
ments which implied that both hydroxy group were located on the
aromatic rings. In fact, the fragment ion at m/z 213.0807, which
was found in both spectra, arose from the shift of 16 u from the ion
at m/z 197. Similarly, the ion at m/z 135.0438, which was observed
in the spectrum of M13, corresponded to m/z 119 plus 16 u and
provided evidence that two hydroxy groups were located on the
same aromatic ring. M14 spectrum showed additional fragments,
namely the ion at m/z 195.0801, which resulted from a loss of water
from the ion at m/z 213, and the ion at m/z 167.0852 that may be
explained by a loss of CO followed by a loss of water from the ion
at m/z 213.
Figure 1. Peak areas of MT-45 and identified metabolites following rat hepatocytes incubation at 0.5, 1, 2 and 3 h.
5Identification of MT-45 Metabolites
Downloaded from https://academic.oup.com/jat/article-abstract/doi/10.1093/jat/bkx058/3978805/Identification-of-MT-45-Metabolites-In-Silico
by Sapienza Università di Roma user
on 12 September 2017
Animal study: in vivo results
Urine analysis
The presence of all metabolites, identified during hepatocyte incuba-
tion, was confirmed in the urine specimens, highlighting the applica-
bility of in vitro hepatocyte experiments for predicting in vivo
metabolites. However we noticed that, in our experimental condi-
tions, glucuronide conjugates were the most abundant metabolites
in the urine specimens, while Phase I metabolites were the most
abundant in the hepatocyte samples; M9 and M10, arising from N-
dealkylation were more abundant in the authentic urine as well.
However considering the different matrices, and the reduced clean-
up for urine specimens (simple dilution) it must be considered that
signal intensities also can be affected by different ionization efficien-
cies and matrix effects. The different intensities between in vitro and
in vivo glucuronides conjugates peaks can also be explained as a
consequence of glomerular filtration taking place in the nephron, in
fact polar molecules are excreted more easily from blood stream,
unlike the lipophilic molecules, which are reabsorbed and conju-
gated. This process does not perform during in vitro experiment.
The results, summarized in Figure 7, showed an extensive bio-
transformation of MT-45 in vivo, in all the animals MT-45 concen-
tration rapidly decreased over time, to be lower than 10 ngmL−1
after 300min. On the other hand at that time, metabolites are still
in considerable amounts (for most metabolites area >105); the detec-
tion of MT-45 metabolites is thus essential to document MT-45 con-
sumption during clinical and forensic urine testing. The results
obtained show the need of synthesize MT-45 metabolites as refer-
ence standards for developing quantitative methods.
Urinary excretion patterns over time showed little inter-subject
variability; N-dealkylated metabolites and OH-MT-45 decrease of
over one order of magnitude after 300min from MT-45 assump-
tion. Di-OH-MT-45 and glucuronide conjugates decrease with a
lower rate, showing a slower biotransformation. For most mice,
Figure 2. MS/MS spectra of MT-45 at different NCE and its fragmentation
pattern.
Figure 3. MS/MS spectra of MT-45 hydroxylated metabolites (M1, M2, M3) at different NCE.
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Figure 4. MS/MS spectra of MT-45 bis-hydroxylated metabolites (M4, M5, M6, M7, M8) at different NCE.
Figure 5. MS/MS spectra of MT-45 metabolites generated by N-dealkylation (M9, M10) at different NCE.
Figure 6. MS/MS spectra of MT-45 Phase II metabolites (M11, M12, M13, M14) at different NCE.
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glucuronides display a double peak; a possible explanation for this
behavior is that glucuronides are deconjugated and reabsorbed, or prob-
ably the different isoforms (M9-M13) are excreted at different times.
Behavioral studies
The threshold to acute mechanical pain stimulus in mice did not
change in saline-treated mice over the 5 h observation (Figure 8 Panel
A) and the response was similar to that observed in naïve untreated
animals (data not shown). Systemic administration of MT-45 and mor-
phine (6mg kg−1 i.p.) increased the threshold to acute mechanical pain
stimulus in mice in the tail pinch test (Figure 8 Panel A: significant
effect of treatment (F2,147 = 336.7, P < 0.0001), time (F6,147 = 27.90,
P < 0.0001) and time × treatment interaction (F12,147 = 6.066, P <
0.0001)). Both drugs show a similar profile, which is characterized by
a maximum analgesic effect at 55min (84.27% ± 4.34% and 91.24%
± 1.34%, respectively). After drug injection, analgesic effects were sus-
tained and prolonged up to 205min.
Respiratory rates did not change in saline-treated mice over the
5 h observation (Figure 8 Panel B) and the response was similar to
that observed in naïve untreated animals (data not shown). Groups
of mice treated with MT-45 and morphine have similar basal respi-
ratory rates (274 ± 6 brp and 260 ± 6 brp, respectively). Systemic
administration of MT-45 and morphine (6 mg kg−1 i.p.) reduced
similarly the respiratory rates in a prolonged way just to 245min
after injection (Figure 8 Panel B: significant effect of treatment
(F2,168 = 48.83, P < 0.0001), time (F7,168 = 5.372, P < 0.0001) and
time × treatment interaction (F14,168 = 1.960, P = 0.0237)). The
maximum effect was reached at 65min for MT-45 (76.14% ±
5.26%) and at 125min for morphine (82.50% ± 6.09%).
Figure 7. In vivo results: urinary concentration of MT-45 and peak areas of metabolites as a function of time after i.p administration of MT-45.
8 Montesano et al.
Downloaded from https://academic.oup.com/jat/article-abstract/doi/10.1093/jat/bkx058/3978805/Identification-of-MT-45-Metabolites-In-Silico
by Sapienza Università di Roma user
on 12 September 2017
Our behavioral data confirm that (racemic) MT-45 produces
similar magnitude in mechanical analgesia and respiratory depres-
sion to morphine (21, 22) suggesting a similar potential for acute
toxicity. Noteworthy, in vivo efficacy of MT-45 seems to overlap
the pattern of the drug metabolism, suggesting that the acute phar-
macological and toxicological activity of MT-45 could be mainly
due to the “parent drug” instead of metabolites. However, further
in vivo studies will be undertaken to better understand the profile of
action of both MT-45 and its major metabolites.
Conclusions
In this work, the chemical structures of 14 Phase I and II MT-45
metabolites were identified using firstly the prediction in silico, then
incubation of the drug with rat hepatocytes was carried out and the
obtained metabolites were recognized by LC–HRMS. The detected
metabolites were confirmed by in vivo experiments.
The structures of the observed metabolites were confirmed based
on retention times, mass shift between theoretical mass and observed
mass (<5 ppm), peak abundance and fragmentation pattern. It
should be stressed that the relative amounts of metabolites were dif-
ferent between in vivo and in vitro experiments, with a prevalence
of Phase II metabolites in real urine specimens while the opposite
was found in vitro experiments.
The detected metabolites are mainly products of mono- or dihy-
droxylation, and N-dealkylation; glucuronide conjugation of mono-
and dihydroxylated metabolites was also observed. Hydroxylated
MT-45 demonstrated to be bioactive (23, 24) and may contribute to
the overall pharmaco-toxicological profile of MT-45 in vivo.
The knowledge of Phase I and II MT-45 metabolite structure is
also needed to develop analytical methods to identify MT-45 con-
sumption in clinical and forensic testing.
Supplementary data
Supplementary data is available at Journal of Analytical Toxicology online.
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